Almi - Scaleup Investor Network (SCIN)
Where innovation meets capital
Almis Scaleup Investor Network (SCIN) is a curated network designed to connect forward-thinking and value creating investors with high-potential scaleups. This is not a “one-off event”, it is a long-term initiative built to foster meaningful relationships, strategic investments, and shared growth.
The network brings together a select group of companies, chosen for their innovation, scalability, and potential to lead in their respective industries.
Our digital pitch sessions are structured, time-efficient, and focused on quality over quantity.
We have already hosted a number of successful pitch workshops – including Alims thematic sessions on for example the Low Altitude Economy, a rapidly emerging segment within the aerospace industry, as well as a broader showcase featuring scaleups from diverse sectors.
Pitches October 15
MyMedicalData Systems MMD AB
MyMedicalData Systems MMD AB develops Hälsa+, a platform and mobile app that collects the individual's health data (e.g. Apple Health/Google Fit, medical records, test results, vaccinations, ECG) and presents personalized dashboards with AI support for prevention. The user can share data securely with caregivers, relatives and research.
For employers, we offer anonymized aggregated real-time analytics for healthier and more engaged teams, which lowers sick leave and strengthens occupational health. The platform is up and running with apps for iOS and Android, and we are finalizing integrations (MMD Connect) as well as AI rollout for paying customers. The goal is scalable B2B licensing, EU-compliant data sharing and positive cash flow in the next stage.
Read about MyMedicalData Systems
NTIBO
NTIBO develops AI-driven drug discovery for difficult-to-target proteins implicated in neurodegeneration, cancer, and aging. Traditional methods fail because these proteins lack fixed structures—our platform uses complementary proteases mapping and deep learning (CNN achieving MCC 0.62) to identify where drugs can bind. We validate therapeutic peptides using AlphaFold3, achieving gold-standard confidence. 4 patents filed (5th in development), quantum-enhanced optimization in development with IBM. Strategic partnerships: IBM Partner Plus, Arrow Electronics funding. Focus: ALS/FTD, Parkinson's, Alzheimer's, SIRT6 longevity pathways. Platform applicable to 30-50% of human proteome previously considered undruggable.
CUBO
At CUBO Biotechnologies, we’re addressing one of the most urgent challenges of our time: the exponential growth of digital data. Today, storing that data is costly, energy-hungry, and contributing to global warming. We believe there’s a better way.
Our breakthrough is producing cheap DNA, nature’s ultimate storage medium. DNA has been storing information for billions of years. By harnessing this super material, we’re unlocking sustainable, ultra-dense, and long-term data archival at a scale the world needs today.
This isn’t incremental change. This is a step-function forward in how we preserves our knowledge, culture.
Offspring Biosciences
Offspring Biosciences is a specialized Contract Research Organization (CRO) providing advanced molecular pathology-based analytical services to pharmaceutical and biotech companies. Since 2012, we have been a trusted partner for clients aiming to accelerate and de-risk their drug development pipelines. We address the critical need for reliable, early-stage data by delivering precision tissue-based analytics. Our services - including target validation, drug binding profiling, and biomarker characterization - enable informed Go/No-Go decisions, reducing costly late-stage failures and saving valuable time and resources. Utilizing cutting-edge technologies such as multiplexed immunohistochemistry, in situ proximity ligation assay, automated workflows, and AI-powered image analysis, we generate robust and actionable data. Our expertise spans key therapeutic areas like neurodegenerative diseases, oncology, and inflammatory disorders. Notably, we have contributed to the development of breakthrough therapeutics such as Leqembi/lecanemab for Alzheimer's disease.
Read about Offspring Biosciences
Pharma Way
Pharma way is the next Swedish growth journey. The Company develops and sells DOT SHOT products - the world’s first and only turmeric drink based on water dispersible curcumins. DOT SHOT is anti-inflammatory with documented health effects.
Turmeric is the most well documented botanical with over 12,000 scientific papers studying the health effects of curcumins the active ingredient of turmeric.
DOT SHOT products (food supplements) contain our proprietary water dispersible curcumins that increase absorption and health effects compared to traditional products, such as powder, capsules and juices.
DOT SHOT is the only curcumin drink in the Swedish service and grocery stores. DOT SHOT shows one of the highest sales values per store when compared to the entire category of functional juices – well above well-established brands such as Garant, Rscued, Innocent and RÅ.
The Company is rapidly increasing its distribution and sales of DOT SHOT products as the Company has during fall been given access to more than 400 COOP stores. The high sales value per store clearly shows great potential for increased distribution and sales data confirm that there is a customer demand for the products.
The world market for turmeric beverages is expected to grow to more than 814 MUSD in 2027. Projected sales 2030: €5 million.
Developeration
We have developed PexyEazy®, a minimally invasive surgical device for treating hemorrhoids – one of the world’s most common conditions. The procedure takes less than 15 minutes, requires no anesthesia, and can be performed as an office treatment, cutting costs dramatically while allowing clinics to double their patient throughput and reimbursement.
Clinical studies show outcomes comparable to the gold standard, but with only one day of sick leave instead of 3–4 weeks. Thanks to its purely mechanical, intuitive design, the device is easy to adopt, requires no special equipment, and works even in settings without electricity – making it scalable worldwide.
With a market projected to exceed $1,3 billion annually by 2030, we see PexyEazy® capturing 25–35% market share by offering a solution that is better for patients, clinicians, and healthcare systems alike.
We are now initiating a $10M Series A financing round in Q3–Q4 2025 to finance our planned market introduction in 2026 in the US and EU.
NAiX Insights
NAiX Insight AB is developing NAiX Care, an AI-driven home care management platform for old adults. By combining real-time health insights based on AI algorithm, we empower caregivers, families, and municipalities to deliver safer, more efficient, and personalized care. Backed by Karolinska Institutet Innovations, we are set to redefine elder care in Sweden and beyond.
HELA RadioPharma
Hela RadioPharma is establishing the Nordic region’s first modern large-scale isotope production facility, with early access to Sumitomo’s high-yield MP-30X cyclotron. The facility will produce At-211, Cu-64, Zr-89 and other critical isotopes at high volume and quality, securing supply for cancer diagnostics and targeted alpha therapy (TAT). By combining strategic partnerships with universities and hospitals (e.g. Karolinska Institute) and a landlord-financed, purpose-built facility next to Karolinska University Hospital, Hela ensures reliable domestic production. This positions Hela as a first-mover in Northern Europe’s isotope market, addressing an urgent global shortage that today delays clinical trials, hinders next-gen therapies, and slows commercialization.
MediTuner
MediTuner, founded at the Karolinska Institute, is a Swedish digital health company transforming respiratory care.
Our CE-marked, patented technology empowers patients with asthma and COPD (affecting 15% of the population) to monitor lung function, track symptoms, and receive instant, individualized treatment instructions.
Our unique algorithms also help clinicians intervene earlier, enabling patients to manage their condition more effectively. We tackle the challenges of poorly managed chronic respiratory diseases, which often lead to preventable hospitalizations and reduced quality of life.
Already reimbursed in Sweden, we are expanding across the Nordics, Europe, and beyond. Large real-world implementations in Swedish primary care have demonstrated improved clinical outcomes while halving unplanned healthcare visits.
By combining digital therapeutics, predictive analytics, and seamless integration with healthcare systems, MediTuner turns reactive asthma care into proactive care. Recognized as ‘Best Digital Technology for Asthma’ by 45 European patient organizations, we are setting a new standard for chronic respiratory disease management.
Health Integrator
Health Integrator is a digital health company operating in the preventive care and public health innovation space. Its core offering is a personalized platform that connects individuals at risk of chronic diseases—particularly type 2 diabetes—with tailored health services, coaching, and lifestyle interventions. The company pioneered Sweden’s first Health Impact Bond, aligning financial incentives with measurable health outcomes.
In partnership with Region Stockholm, Health Integrator delivered a large-scale prevention program targeting individuals with prediabetes. The results speak for themselves:
57.3% of participants who completed the program achieved normal blood sugar levels (HbA1c <42 mmol/mol), effectively reversing their prediabetes status.
The intervention led to a 73.5% reduction in diabetes risk compared to expected progression without lifestyle support.
The program also demonstrated statistically significant reductions in BMI and 84% of the user experience better mental health and quality of life
The Health Impact Bond delivered a full financial return to investors, validating both the health and economic model.
Health Integrator’s mission is to scale evidence-based prevention, reduce healthcare costs, and shift systems from reactive treatment to proactive health promotion.
Firglas
Firglas has built a microalgae facility in Spain to cultivate microalgae in sunlight. with cost and operational advantages. The objective is to demonstrate viability at scale in terms of yield, efficiency and sustainability. The facility binds CO₂ using sunlight in Mediterranean seawater to produce highly nutritious sustainable algae-based products for aquaculture, nutraceuticals and ingredients.
Precision Biopsies
We offer an innovative technology for tumor diagnostics and prediction of treatment effectiveness, based on patient-friendly fine needle biopsies. Precision Biopsies (PB) builds on the latest developments in genetics and protein analysis of tumors and provides more accurate diagnoses and predictions about which therapy to use in individual cases. PB also uses AI-based tools for these purposes. This technology will accelerate tumor diagnostics and improve health economics.
Potential customers include private healthcare providers, pharmaceutical companies, and certain public healthcare institutions. We offer analyses ranging from early diagnostics to longitudinal follow-up, where the use of fine needle biopsy has major advantages due to its non-invasive nature, low risk of complications, and comprehensive information for precision cancer therapy. In addition to its role in direct cancer care and in relation to drug treatment, it provides pharmaceutical companies with the opportunity to evaluate their drugs earlier (providing information on drugs in clinical trials and the frequency of target molecules for drugs in development).
The company is in an early stage with a very high level of scientific excellence from a clinical perspective and significant international market potential. There is a favorable competitive position internationally, where PB is at the forefront of this new technology. In the US, the company Tempus – partially similar profile but is not based on fine needle technology – currently has annual sales of one billion US dollars. The Institute for Health Economics is currently investigating the health economic benefits of our technology.
NeoGap
About the company: Neogap Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using the patient’s own cells.
pTTL (personalised Tumour Trained Lymphocytes) is a cell-based immunotherapy that enhances the patient’s own T cells to fight cancer. It combines sophisticated DNA sequencing with T-cell expansion to deliver a personalised, precision cancer treatment.
The therapy is currently being evaluated in a Phase I/II clinical trial for advanced colorectal cancer and holds potential for broader application in cancer treatment. Powered by Neogap’s proprietary technologies, PIOR® and EpiTCer®, the pTTL therapy is designed to provide patients with a tailored and innovative therapy that meets their specific needs.
Curevo Health
Curevo Health delivers specialist-led digital care that integrates seamlessly with primary care. We move patients from referral to treatment within days instead of months. Funded solely through the standard patient fee, our care is both sustainable and profitable, creating a model with no financial burden on clinics, regions, or public funds. Our system preserves GP continuity while AI automation handles everything from anamnesis to documentation, making high-quality specialist care up to 87 percent more cost-efficient.
The model is scalable, fully compatible with the existing healthcare system, and designed to relieve pressure on physical care. The result is shorter queues, lower system costs, and more time for human care. Currently we have signed well known angels with insights and contact networks in the market such as Claes Dinkelspiel (founder of Nordnet and Öhman group), Johan Färnstrand (former CEO of Aleris) and the chief psychiatrist Alexander Tsegaye .
Tidigare pitchtillfällen
Här hittar du bolag som har varit med under tidigare pitchtillfällen.
